2 active not recruiting, 2 unknown, 1 terminated, 1 withdrawn. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Active not recruiting 2, Unknown 2, Terminated 1, Withdrawn 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 3 | 1 | Active not recruiting 1 |
Follow Tuberculosis Infection: new trials by email Literature Review of Tuberculosis Infection trials Research Report on Tuberculosis Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV Rifapentine, Isoniazid - HIV Seropositivity, Pregnancy | Phase 1 / Phase 2 | Active not recruiting | The Aurum Institute NPC | 252 | 2024-01-17 | 2025-12-12 |
| Short-course Regimens for the Treatment of Pulmonary Tuberculosis Rifabutin, Delamanid, Bedaquiline - Tuberculosis, Pulmonary, Tuberculosis Infection | Phase 2 / Phase 3 | Active not recruiting | Centers for Disease Control and Prevention | 288 | 2023-11-21 | 2026-09-21 |
| Adjunctive Acetylsalicylic Acid and Ibuprofen for Tuberculosis Control group, ASA group, IBU group - Tuberculosis, Pulmonary, Tuberculosis, MDR | Phase 2 | Terminated | Fundació Institut Germans Trias i Pujol | 426 | 2021-03-04 | 2026-06-01 |
| A Phase II Study of H56:IC31 in Healthy Adolescents H56:IC31, Placebo - Tuberculosis Infection | Phase 2 | Withdrawn | Aeras | 2018-06-01 | 2018-04-10 | |
| Equivalence Study of Specificity of PPD Aplisol@ PPD material, Reference Standard - Tuberculosis Infection | Phase 2 | Unknown | JHP Pharmaceuticals LLC | 152 | 2013-02-01 | 2013-02-25 |
| Dose Study of Tuberculin Purified Protein Derivative (JHP/Dose) To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard., Reactivity of Aplisol compared to reference standard PPD-S2. - Tuberculosis Infection | Phase 2 | Unknown | JHP Pharmaceuticals LLC | 168 | 2012-05-01 | 2012-09-21 |
Latent Tuberculosis (6) · Tuberculosis, Pulmonary (2) · Communicable Diseases (1) · HIV Seropositivity (1) · Tuberculosis (1) · Tuberculosis, Multidrug-Resistant (1)
Actinomycetales Infections (6) · Bacterial Infections (6) · Bacterial Infections and Mycoses (6) · Gram-Positive Bacterial Infections (6) · Infections (6) · Latent Infection (6) · Mycobacterium Infections (6) · Tuberculosis (5) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Respiratory Tract Infections (2) · Blood-Borne Infections (1) · Communicable Diseases (1) · Disease Attributes (1) · Genital Diseases (1)
Isoniazid (2) · Aspirin (1) · Control Groups (1) · Ethambutol (1) · Ibuprofen (1) · Moxifloxacin (1) · OPC-67683 (1) · Pyrazinamide (1) · Reference Standards (1) · Rifabutin (1) · Rifampin (1) · Tuberculin (1) · bedaquiline (1) · rifapentine (1)
JHP Pharmaceuticals LLC (2) · Aeras (1) · Centers for Disease Control and Prevention (1) · Fundació Institut Germans Trias i Pujol (1) · The Aurum Institute NPC (1)
South Africa (4) · United States (3) · Canada (1) · Georgia (1) · Haiti (1) · Tanzania (1) · Uganda (1) · Vietnam (1)
Cristina Vilaplana, MD, PhD (1) · Daniel W Fitzgerald, MD (1) · Dereck Tait, MD (1) · Dr Vaneshree Govender (1) · Ekaterina V Kurbatova, MD, PhD, MPH (1) · Kelly Dooley, MD (1) · Wendy Carr, PhD (1)